Aurobindo Pharma Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Quarterly Results    (AUBD)

Here are the latest quarterly results of Aurobindo Pharma. For more details, see the Aurobindo Pharma financial fact sheet and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Aurobindo Pharma Quarterly Results

No. of Mths
Qtr. Ending
3
Mar-18
*
3
Jun-18
*
3
Sep-18
*
3
Dec-18
*
3
Mar-19
*
3
Jun-19
*
3
Sep-19
*
3
Dec-19
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m40,49142,50347,51452,69752,92254,44656,00557,994 
Other income Rs m438437263639323158206309 
Turnover Rs m40,92942,94047,77753,33553,24554,60456,21158,304 
Expenses Rs m32,61035,39237,65141,83342,34742,98244,60346,870 
Gross profit Rs m7,8847,1119,59410,61310,21511,33711,27511,951 
Depreciation Rs m1,5661,5451,6371,6311,8662,4092,4332,501 
Interest Rs m247295354477501499409371 
Profit before tax Rs m6,5095,7077,8669,1448,1708,5878,6389,388 
Tax Rs m1,2241,1551,7542,0482,3112,2782,2442,329 
Profit after tax Rs m5,2854,5526,1127,0965,8596,3106,3957,060 
Gross profit margin %19.516.720.220.119.320.820.120.6 
Effective tax rate %18.820.222.322.428.326.526.024.8 
Net profit margin %13.110.712.913.511.111.611.412.2 
Diluted EPS Rs 9.0 7.8 10.4 12.1 10.0 10.8 10.9 12.1  
Diluted EPS (TTM) Rs 41.4 40.3 37.4 39.4 40.4 43.4 43.9 43.8  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: Aurobindo Pharma 3QFY20 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   SUN PHARMA  PROCTER & GAMBLE HEALTH  IPCA LABS  TORRENT PHARMA  ORCHID PHARMA LTD  

Compare AUROBINDO PHARMA With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  IPCA LABS  TORRENT PHARMA  ORCHID PHARMA LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Views on news

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus (Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Real Long-Term Impact of the Coronavirus on India (The 5 Minute Wrapup)

Mar 18, 2020

My view on the impact of the Coronavirus on the Indian economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Mar 27, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS